Kuros Biosciences (CSBTF) Price & Analysis

Compare

14 Followers

CSBTF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$18.95 - $38.04

Previous CloseN/A

Volume4.47K

Average Volume (3M)139.00

Market Cap

$1.16B

Enterprise Value$1.03B

Total Cash (Recent Filing)$17.46M

Total Debt (Recent Filing)$1.79M

Price to Earnings (P/E)―

Beta0.08

Next Earnings

Mar 10, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding38,613,640

10 Day Avg. Volume118

30 Day Avg. Volume139

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.89

Enterprise Value/Revenue13.68

Enterprise Value/Gross Profit15.55

Enterprise Value/Ebitda2.23K

Forecast

1Y Price Target

$40.72

Price Target Upside26.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Kuros Biosciences News

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

3d ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

23d ago

Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences reported a 78% increase in total medical...

24d ago

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported an 82% year-over-year increase...

5M ago

Kuros Biosciences Reports Strong Revenue Growth in 2024

Kuros Biosciences ( ($CSBTF) ) has released its Q4 earnings. Here is a breakdown of the information Kuros...

6M ago

Kuros Biosciences Achieves Record Growth and Strategic Expansion in 2024

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported a significant increase in...

6M ago

CSBTF FAQ

What was Kuros Biosciences Ltd.’s price range in the past 12 months?

Kuros Biosciences Ltd. lowest stock price was $18.95 and its highest was $38.04 in the past 12 months.

What is Kuros Biosciences Ltd.’s market cap?

Kuros Biosciences Ltd.’s market cap is $1.16B.

When is Kuros Biosciences Ltd.’s upcoming earnings report date?

Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 10, 2026 which is in 184 days.

How were Kuros Biosciences Ltd.’s earnings last quarter?

Kuros Biosciences Ltd. released its earnings results on Aug 14, 2025. The company reported -$0.065 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.065.

Is Kuros Biosciences Ltd. overvalued?

According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences Ltd. pay dividends?

Kuros Biosciences Ltd. does not currently pay dividends.

What is Kuros Biosciences Ltd.’s EPS estimate?

Kuros Biosciences Ltd.’s EPS estimate is 0.

How many shares outstanding does Kuros Biosciences Ltd. have?

Kuros Biosciences Ltd. has 38,613,640 shares outstanding.

What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?

Kuros Biosciences Ltd. reported an EPS of -$0.065 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.669%.

Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?

Currently, no hedge funds are holding shares in CSBTF

Company Description

Kuros Biosciences Ltd.

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Kuros Biosciences (CSBTF) Earnings & Revenues

Historic Earnings Reports

CSBTF Company Deck

CSBTF Earnings Call

Q2 2025

0:00 / 0:00

CSBTF Stock 12 Month Forecast

Average Price Target

$40.72

▲(26.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","20":"$20","27":"$27","34":"$34","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.7207125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.7207125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,20,27,34,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.02,37.3046701923077,37.58934038461539,37.87401057692308,38.15868076923077,38.443350961538464,38.72802115384616,39.012691346153844,39.29736153846154,39.58203173076923,39.866701923076924,40.15137211538461,40.436042307692304,{"y":40.7207125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.02,37.30461538461539,37.589230769230774,37.87384615384616,38.15846153846154,38.44307692307692,38.72769230769231,39.012307692307694,39.29692307692308,39.581538461538464,39.86615384615384,40.15076923076923,40.43538461538461,{"y":40.72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.02,37.3046701923077,37.58934038461539,37.87401057692308,38.15868076923077,38.443350961538464,38.72802115384616,39.012691346153844,39.29736153846154,39.58203173076923,39.866701923076924,40.15137211538461,40.436042307692304,{"y":40.7207125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.22,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.29,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.65,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.42,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.06,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.12,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.82,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >